AZD3514 is primarily used in cancer research, particularly in the study of androgen receptor signaling pathways. It functions as a selective inhibitor of the androgen receptor, which plays a key role in the progression of prostate cancer. By modulating receptor activity and reducing its expression, AZD3514 has been investigated for its potential to slow tumor growth in hormone-sensitive cancers. It is not used clinically but serves as a research tool to understand resistance mechanisms in prostate cancer and to explore new therapeutic strategies involving androgen receptor downregulation. Studies have also looked into its oral bioavailability and pharmacodynamic effects in preclinical models.